Michael Cookson to Neoplasm Invasiveness
This is a "connection" page, showing publications Michael Cookson has written about Neoplasm Invasiveness.
Connection Strength
1.551
-
Advances in the management of castration resistant prostate cancer. BMJ. 2016 Oct 17; 355:i4405.
Score: 0.130
-
Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015 Jan; 67(1):165-170.
Score: 0.107
-
Surgical and chemotherapeutic management of regional lymph nodes in bladder cancer. J Urol. 2012 Oct; 188(4):1081-8.
Score: 0.097
-
Complications of pelvic lymph node dissection for prostate cancer. Curr Urol Rep. 2011 Jun; 12(3):203-8.
Score: 0.089
-
Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009 Oct; 104(8):1091-7.
Score: 0.077
-
A critical review of clinical practice guidelines for the management of clinically localized prostate cancer. J Urol. 2008 Aug; 180(2):451-9; discussion 460.
Score: 0.073
-
Non-muscle-invasive bladder cancer: the role of radical cystectomy. Urology. 2005 Nov; 66(5):917-22.
Score: 0.061
-
Radical cystectomy for bladder cancer: the case for early intervention. Urol Clin North Am. 2005 May; 32(2):147-55.
Score: 0.059
-
The surgical management of muscle invasive bladder cancer: a contemporary review. Semin Radiat Oncol. 2005 Jan; 15(1):10-8.
Score: 0.057
-
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
Score: 0.055
-
Advances in diagnosis and treatment of bladder cancer. BMJ. 2024 02 12; 384:e076743.
Score: 0.054
-
Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol. 2003 Jan; 169(1):101-4.
Score: 0.050
-
Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol. 2002 May; 167(5):2032-5; discussion 2036.
Score: 0.048
-
Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol. 2002 Feb; 167(2 Pt 1):502-5.
Score: 0.047
-
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
Score: 0.046
-
Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. J Urol. 2022 01; 207(1):70-76.
Score: 0.045
-
Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol. 2021 Dec; 39(12):4345-4354.
Score: 0.045
-
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
Score: 0.043
-
Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. J Urol. 2016 Oct; 196(4):1030-5.
Score: 0.031
-
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014 Oct; 11(10):589-96.
Score: 0.028
-
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9.
Score: 0.028
-
Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Urology. 2014 Jun; 83(6):1309-15.
Score: 0.027
-
Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology. 2014 Jan; 83(1):75-80.
Score: 0.026
-
Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist. Urology. 2013 Jun; 81(6):1123-30.
Score: 0.025
-
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):45-57.
Score: 0.024
-
Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One. 2012; 7(5):e36669.
Score: 0.024
-
Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology. 2011 Jul; 78(1):99-104.
Score: 0.022
-
Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU Int. 2009 Oct; 104(7):934-7.
Score: 0.019
-
Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer. 2009 Feb 15; 115(4):770-5.
Score: 0.019
-
Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol. 2009 Feb; 181(2):540-5; discussion 546.
Score: 0.019
-
Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol. 2007 Oct; 178(4 Pt 1):1418-21; discussion 1421-2.
Score: 0.017
-
Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. J Urol. 2004 Sep; 172(3):882-4.
Score: 0.014
-
Adverse prognostic significance of capsular incision with radical retropubic prostatectomy. J Urol. 2004 Jul; 172(1):119-23.
Score: 0.014
-
Benefit of radical cystectomy in the elderly patient with significant co-morbidities. Urol Oncol. 2004 May-Jun; 22(3):178-81.
Score: 0.014
-
Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003 Oct; 170(4 Pt 1):1085-7.
Score: 0.013